You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Canagliflozin: A new option for managing diabetes

Livingston, Molly PharmD; Clements, Jennifer N. PharmD, BCPS, CDE, BCACP

Journal of the American Academy of Physician Assistants:
doi: 10.1097/01.JAA.0000453247.76333.09
What's New in Diabetes
Abstract

ABSTRACT: Canagliflozin is a sodium glucose cotransporter 2 inhibitor for patients with type 2 diabetes and can be given as monotherapy or in combination with other agents, including insulin. Taken orally once daily, canagliflozin can reduce weight and BP, but has been associated with genital mycotic infections.

Author Information

At the time this article was written, Molly Livingston was a student in the doctor of pharmacy program at Presbyterian College School of Pharmacy in Clinton, S.C. Jennifer N. Clements is an associate professor in the Department of Pharmacy Practice at Presbyterian College School of Pharmacy.

The authors have disclosed no potential conflicts of interest, financial or otherwise.

Mark E. Archambault, DHSc, PA-C, department editor

© 2014 American Academy of Physician Assistants.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.